NLK expression is also reduced in prostate metastasis, hepatocellular carcinoma, and glioblastoma with less favorable clinical outcomes, suggesting NLK can serve as an oncogene or tumor suppressor, depending on cell context. The gene discussed is NLK; the disease is hepatocellular carcinoma.